Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DRUG USE INVESTIGATION OF BOSUTINIB FOR CML (POST MARKETING COMMITMENT PLAN)

NCT02501330 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02501330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02501330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DRUG USE INVESTIGATION OF BOSUTINIB FOR CML (POST MARKETING COMMITMENT PLAN)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
July 1, 2015
Completion date
February 28, 2024
Enrollment
702 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia